Although it is referred to as a weak estrogen and was used solely as an estrogen in clinical practice, CTA is a [[partial agonist]] of the [[estrogen receptor]].<ref name="Sneader2005" /> As such, it is a [[selective estrogen receptor modulator]] (SERM), with predominantly estrogenic but also [[antiestrogen]]ic effects, and was arguably the first SERM to ever be introduced.<ref name="FischerGanellin2012">{{cite book|author1=Janos Fischer|author2=C. Robin Ganellin|author3=David P. Rotella|title=Analogue-based Drug Discovery III|url=https://books.google.com/books?id=BP2Bo11gTOMC&pg=SA5-PA56|date=15 October 2012|publisher=John Wiley & Sons|isbn=978-3-527-65110-8|pages=5–}}</ref> CTA can antagonize [[estradiol]] at the level of the [[hypothalamus]], resulting in disinhibition of the [[hypothalamic-pituitary-gonadal axis]] and an increase in estrogen levels.<ref name="Sneader2005" /> [[Clomifene]] and [[tamoxifen]] were both derived from CTA via structural modification, and are much weaker partial agonists than CTA and hence much more antiestrogenic in comparison.<ref name="Sneader2005" /> As an example, chlorotrianisene produces [[gynecomastia]] in men,<ref name="Li2009">{{cite book|author=Jie Jack Li|title=Triumph of the Heart: The Story of Statins|url=https://books.google.com/books?id=-GPl1PA5EgMC&pg=PA34|date=3 April 2009|publisher=Oxford University Press, USA|isbn=978-0-19-532357-3|pages=34–}}</ref> albeit reportedly to a lesser extent than other estrogens,<ref>{{cite book|title=VITAMINS AND HORMONES|url=https://books.google.com/books?id=5ZbLRONHoDoC&pg=PA387|date=18 May 1976|publisher=Academic Press|isbn=978-0-08-086630-7|pages=387–}}</ref> while clomifene and tamoxifen do not and can be used to treat gynecomastia.<ref name="Khan2003">{{cite journal|last1=Khan|first1=H. N|title=Endocrine treatment of physiological gynaecomastia|journal=BMJ|volume=327|issue=7410|year=2003|pages=301–302|issn=0959-8138|doi=10.1136/bmj.327.7410.301}}</ref>
